Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elevance Health, Inc. filings document formal disclosures for a health benefits and healthcare services company, including Form 8-K reports of quarterly and annual results, earnings guidance, benefit expense ratio updates, and Regulation FD communications. The filings also cover leadership changes, Carelon oversight, board appointments, committee assignments, and executive compensation matters reported through proxy materials.
Its regulatory documents include risk and operating disclosures tied to Health Benefits, Carelon, pharmacy and diversified healthcare services, provider contracting, product mix, government program funding, CMS Star Ratings, litigation, investigations, audits and professional-liability exposure. Recent 8-K disclosures also address CMS oversight of the company's Medicare Advantage-Prescription Drug plans.
Elevance Health, Inc. executive Felicia F. Norwood reported equity compensation activity and related tax-withholding transactions. She received grants of 5,951 common shares and 2,865 performance-based restricted share units, plus an employee stock option covering 23,512 shares with future vesting installments.
To satisfy tax liabilities upon vesting of previously granted restricted stock, 496 common shares at $284.03 per share and 1,421 common shares at $294.07 per share were disposed of through stock withholding rather than open-market sales. Following these transactions, she directly owned 38,838 common shares.
Elevance Health EVP & Chief Digital Information Officer Ratnakar Lavu reported multiple equity compensation transactions. He received a grant of employee stock options covering 20,152 shares at an exercise price of $0.00 per share, exercisable in three installments beginning on 3/2/2027. He also acquired 5,101 and 6,802 shares that the footnotes describe as restricted share units with restrictions lapsing between 3/2/2027 and 3/2/2029. In separate transactions, 222 shares at $284.03 per share and 315 shares at $294.07 per share were withheld as common stock to satisfy tax liabilities on previously granted restricted stock vesting, rather than open-market sales.
Elevance Health EVP & President, Commercial, Kendrick Charles Morgan Jr. reported routine equity compensation changes. On March 2, 2026, he received 15,870 employee stock options exercisable in three equal annual installments starting on March 2, 2027, plus 6,549 common shares through restricted and performance-based stock unit awards. On March 2 and 3, 2026, a total of 1,678 common shares were disposed of at prices around $294.07 and $284.03, respectively, solely to cover tax liabilities upon vesting, leaving direct ownership of common stock.
Elevance Health EVP Peter D. Haytaian reported equity compensation activity in company common stock. On March 3, 2026, 446 shares were withheld at $284.03 per share, and on March 2, 2026, 1,201 shares were withheld at $294.07 per share to cover tax liabilities upon vesting of previously granted restricted stock. Also on March 2, he received a grant of 2,865 performance-based restricted share units as an award, bringing his directly held stake to 27,668 shares after these transactions.
Elevance Health EVP & CFO Mark Kaye reported multiple equity compensation transactions. He received grants of 6,377 and 10,202 restricted stock units, with restrictions scheduled to lapse between March 2, 2027 and March 2, 2029, and a stock option covering 25,188 shares exercisable in three annual installments beginning on March 2, 2027.
To cover tax liabilities tied to previously granted restricted stock vesting, he disposed of 353 and 271 common shares at prices of $284.03 and $294.07 per share through share withholding, rather than open-market sales.
Elevance Health President and CEO Gail Boudreaux reported a mix of equity grants and tax-related share dispositions. She received a grant of 63,818 employee stock options exercisable in three annual installments beginning on 3/2/2027. She was also awarded 16,153 and 10,527 common shares as restricted share unit and performance-based restricted share unit grants. To cover tax liabilities upon vesting of previously granted restricted stock, 1,736 common shares at $284.03 per share and 6,713 shares at $294.07 per share were withheld. After these transactions, she held 169,251 common shares directly, and 60 additional shares were reported as held indirectly in her spouse's revocable trust.
Elevance Health disclosed that the Centers for Medicare & Medicaid Services plans to impose intermediate sanctions on its Medicare Advantage-Prescription Drug plans. The sanctions would suspend new Medicare beneficiary enrollment and certain communications starting March 31, 2026, if CMS is not satisfied that identified issues are resolved.
CMS indicated the proposed sanctions relate to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for services before April 3, 2023. Elevance Health states that it revised its practices in April 2023 after additional regulatory guidance and is working cooperatively with CMS. The suspension does not affect current members’ existing benefits or plans.
Elevance Health announced management changes and reaffirmed its 2026 financial outlook. Executive Vice President and Carelon President Peter D. Haytaian will leave his Carelon role effective May 4, 2026 to focus on family, and will serve as Special Advisor through December 31, 2026 to support a smooth transition.
Chief Financial Officer Mark Kaye will add oversight of Carelon, the company’s healthcare services operations, while Felicia Norwood will lead a consolidated Health Benefits organization under a single accountable structure. Elevance Health reaffirmed full-year 2026 shareholders’ earnings guidance of at least $22.30 per diluted share, including about $3.20 of net unfavorable items, and at least $25.50 per diluted share on an adjusted basis. The company also reaffirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.
Elevance Health is one of the largest U.S. health insurers, serving about 45.2 million medical members as of December 31, 2025. It operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
The company offers commercial, Medicare, Medicaid, federal employee and specialty plans, and earns revenue from risk-based premiums, self‑funded administrative fees, and pharmacy and health service fees. About 32% of consolidated revenue in 2025 came from U.S. government agencies. Elevance leverages Blue Cross and Blue Shield licenses in multiple states, value‑based provider contracts, and digital tools such as its Sydney Health platform to manage costs and quality.
CarelonRx provides pharmacy benefit management and infusion services, while Carelon Services integrates physical, behavioral, pharmacy and social‑care capabilities. The 10‑K highlights extensive regulation under the ACA, the IRA, Medicaid redeterminations, transparency and privacy rules, and notes that results depend heavily on medical cost trends, membership mix and CMS Star Ratings. The company reports a global workforce of roughly 97,100 employees and emphasizes culture, inclusion and fair pay.
Elevance Health, Inc. director Amy W. Schulman reported an acquisition of 218 shares of Company common stock on February 2, 2026. The Form 4 shows these as an "A" transaction at a price of $0 per share, held as direct ownership after the transaction.
The 218 shares reflect phantom stock units accrued under Elevance Health’s Board of Directors Compensation Program. According to the terms, these phantom stock units will be settled in Company common stock on the earlier of five years after the preceding annual shareholder meeting or when Schulman ceases to serve on the board, unless she has elected a later deferral date.